AnalystsDev PrasadDev Prasad's Stock Forecasts
AnalystsDev Prasad
Sectors:
Industries:
Analyst Ranking
Top 30%
#1567 out of 5256 analysts
Average Return
+135.4%
Win Rate
80%4 out of 5
Risk vs Reward
Poor
Good
Dev Prasad's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Opus Genetics IncIRD | +499.57% | $0.92 | $5.54 | 2025-06-16 - 2026-04-20 | Strong Buy |
Avalo Therapeutics IncAVTX | +100.64% | $9.38 | $18.82 | 2024-12-16 - 2025-12-16 | Strong Buy |
Calcimedica IncCALC | +87.77% | $2.78 | $5.22 | 2024-12-16 - 2025-12-16 | Strong Buy |
Cue Biopharma IncCUE | +3.91% | $0.82 | $0.85 | 2025-08-24 - 2026-04-20 | Strong Buy |
Dev Prasad Analyst Color
Get additional color on Dev Prasad's coverage of popular stocks
Dev Prasad's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Atyr Pharma IncATYR | 1 | Hold | $1.00 | +17.23% | Downgrades | 7 months ago |
Cue Biopharma IncCUE | 1 | Strong Buy | $4.00 | +370.59% | Initiates Coverage On | 8 months ago |
Opus Genetics IncIRD | 1 | Strong Buy | $5.00 | -9.75% | Initiates Coverage On | 10 months ago |
Avalo Therapeutics IncAVTX | 1 | Strong Buy | $24.00 | N/A | Initiates Coverage On | a year ago |
Ibio IncIBIO | 1 | Strong Buy | $6.00 | N/A | Initiates Coverage On | a year ago |
Calcimedica IncCALC | 1 | Strong Buy | $13.00 | N/A | Initiates Coverage On | a year ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.